gsk2402968
Muscular Dystrophy
GlaxoSmithKlinePhase 3Dormant
BB
70/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 60/ 100
- Competitive Position
- 89/ 100
Competitive context
5 Active assets in the Muscular Dystrophy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ataluren PTC Therapeutics | Phase 3 | B |
Enalapril InCor Heart Institute | Phase 3 | B |
Aoc 1044 Avidity Biosciences, Inc. | Phase 3 | B |
Deramiocel Capricor Inc. | Phase 3 | B |
Tadalafil University of Florida | Phase 2 | B |
View all 11 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →